SE435507B - PROCEDURE FOR THE PREPARATION OF TRIMETOXIFENOXY-PROPYL-PIPEREZINE DERIVATIVES - Google Patents

PROCEDURE FOR THE PREPARATION OF TRIMETOXIFENOXY-PROPYL-PIPEREZINE DERIVATIVES

Info

Publication number
SE435507B
SE435507B SE7803742A SE7803742A SE435507B SE 435507 B SE435507 B SE 435507B SE 7803742 A SE7803742 A SE 7803742A SE 7803742 A SE7803742 A SE 7803742A SE 435507 B SE435507 B SE 435507B
Authority
SE
Sweden
Prior art keywords
carbon atoms
acid
group
piperazine
groups
Prior art date
Application number
SE7803742A
Other languages
Swedish (sv)
Other versions
SE7803742L (en
Inventor
A Kleemann
V Jakovlev
K Thiemer
J Engel
Original Assignee
Degussa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Degussa filed Critical Degussa
Publication of SE7803742L publication Critical patent/SE7803742L/en
Publication of SE435507B publication Critical patent/SE435507B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/80Acids; Esters in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/24Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

p 1ao3742+1 cnßo 01130 o-cxiz-fx-cnz-N N-RZ I- - en o _ OR 3 1 vari Rl betecknar väte, alkanoyl med 2 - 6 kolatomer, alkenoyl med 3 - 6 kolatomer, bensoyl, alkoxibensoyl med l - 4 kolatomer, niko- tinoyl eller tienylkarbonyl och R2 betecknar en eventuellt med grup- perna R3 och R4 substituerad fenyl-, naftyl- eller pyridylgrupp, vari R3 och R4 är lika eller olika och betecknar väte, hydroxyl, fluor, klor, brom, nitro, trifluormetyl, alkyl med 1 - 6 kolatomer, alkoxi med la- 6 kolatomer, alkyltio med l - 6 kolatomer. alkanoyl med 2 - 6 kolatomer, amino, acylamino eller acyloxi, varvid i de båda sistnämnda grupperna acyl kan vara en för Rl angiven acylgrupp, och deras salter. p 1ao3742 + 1 cnßo 01130 o-cxiz-fx-cnz-N N-RZ I- - en o _ OR 3 1 wherein R1 represents hydrogen, alkanoyl having 2 to 6 carbon atoms, alkenoyl having 3 to 6 carbon atoms, benzoyl, alkoxybenzoyl with 1-4 carbon atoms, nicotinoyl or thienylcarbonyl and R 2 represents a phenyl, naphthyl or pyridyl group optionally substituted by the groups R 3 and R 4, wherein R 3 and R 4 are the same or different and represent hydrogen, hydroxyl, fluorine, chlorine, bromine , nitro, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkylthio of 1 to 6 carbon atoms. alkanoyl having 2 to 6 carbon atoms, amino, acylamino or acyloxy, wherein in the latter two groups acyl may be an acyl group indicated for R1, and their salts.

Alkanoyl- och alkenoylgrupperna kan vara raka eller grenade.The alkanoyl and alkenoyl groups may be straight or branched.

Alkanoylgrupperna har företrädesvis 2, 3 eller 4 kolatomer, alkenoyl~ gruppen företrädesvis 3, 4 eller 5 kolatomer. Tienylgruppen kan utgöras av motsvarande tienyl-(2)- resp. tienyl-(3)-karbonylgrupp.The alkanoyl groups preferably have 2, 3 or 4 carbon atoms, the alkenoyl group preferably 3, 4 or 5 carbon atoms. The thienyl group may consist of the corresponding thienyl (2) - or thienyl (3) -carbonyl group.

Ifrågavarande alkylgrupper i alkyl-, alkoxi- och alkyltiogrup- perna kan vara raka eller grenade. Exempel härpå är metyl, etyl, propyl, isopropyl, metoxi, etoxi, propoxi, isopropoxi, butoxi, tert.- butoxi, metyltio, etyltio, propyltio och butyltio. Exempel på acyl- aminogruppen är acetamino och bensoylamino. Om R2 betecknar en naftyl- grupp, kan denna utgöras av naftyl-(l)- eller naftyl-(2)-gruppen, varvid denna naftylgrupp i båda ringarna kan vara substituerad med grupperna R3 och R4. Företrädesvis är dock naftylringen substituerad i den 6-ring, som inte är sammankopplad med piperazinringen. Om R2 betecknar en pyridylring, kan denna vara sammankopplad med piperazin- ringen i 2-, 3- eller 4-ställning.The alkyl groups in the alkyl, alkoxy and alkylthio groups may be straight or branched. Examples are methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, methylthio, ethylthio, propylthio and butylthio. Examples of the acylamino group are acetamino and benzoylamino. If R 2 represents a naphthyl group, this may be the naphthyl (1) or naphthyl (2) group, this naphthyl group in both rings being substituted by the groups R 3 and R 4. Preferably, however, the naphthyl ring is substituted in the 6-ring, which is not linked to the piperazine ring. If R2 represents a pyridyl ring, this can be connected to the piperazine ring in the 2-, 3- or 4-position.

Rl betecknar exempelvis väte eller alkanoyl med 2, 3 eller 4 kolatomer.R 1 represents, for example, hydrogen or alkanoyl having 2, 3 or 4 carbon atoms.

Om R2 betecknar én fenyl- eller pyridylgrupp, befinner sig substituenterna R3 och/eller R4 företrädesvis i den ställning som angränsar till det ställe, där R2 är sammankopplad med piperazin- 3 7eas742-1 ringen.If R 2 represents one phenyl or pyridyl group, the substituents R 3 and / or R 4 are preferably in the position adjacent to the site where R 2 is attached to the piperazine ring.

Företrädesvis betecknar Rl väte od1R2 en alkoxifenylgrupp med 1 - 4 kolatomer (exempelvis metoxifenyl, etoxifenvl) hydroxi- fenvl, aminofenyl, alkanoylaminofiayl med 2 - 4 kolatomer (exempelvis acetylaminofenyl, propionylaminofenyl) eller en alkanoyloxifenvl~ grupp med 2 -4 kolatomer (exempelvis acetoxifenyl, propionyloxi- fenyl) varvid dessa substituenter står i o- eller p-ställning, företrädesvis i o-ställning.Preferably R 1 hydrogen or 1 R 2 represents an alkoxyphenyl group having 1 to 4 carbon atoms (for example methoxyphenyl, ethoxyphenyl) hydroxyphenyl, aminophenyl, alkanoylamino-ayl having 2 to 4 carbon atoms (for example acetylaminophenyl, propionylaminophenyl) or an alkanoyloxy-2-oxyloxyphenyl propionyloxyphenyl) wherein these substituents are in the o- or p-position, preferably in the o-position.

De nya föreningarna är farmakodynamiskt verksamma och besitter exempelvis en utpräglad antiaggressiv effekt samt neuro- leçmiska egenskaper, varvid antikonvulsiva och hypnotiska effekter endast förefinns i ringa grad eller saknas. Dessutom besitter de febersänkande och ödemhämmande effekter. Enligt uppfinningen tillhandahålles föreningar med gynnsamma farmakodynamiska egenskaper, som kan användas som läkemedel.The new compounds are pharmacodynamically active and possess, for example, a pronounced anti-aggressive effect as well as neurolemic properties, whereby anticonvulsant and hypnotic effects are only present to a small degree or are absent. In addition, they possess antipyretic and anti-edema effects. According to the invention there are provided compounds with favorable pharmacodynamic properties which can be used as medicaments.

I motsats till föreningarna enligt uppfinningen besitter de i den tyska offentliggörandeskriften 2 235 597 beskrivna få-(5,6, 7,8-tetrahydro-nafty1-(l)- oxipropyl]-piperazin-derivaten blod- tryckssänkandeochdärmed antihypertensiva egenskaper. I motsats härtill uppvisar föreningarna enligt uppfinningen ingen eller endast ringa blodtrycksänkande effekt.In contrast to the compounds of the invention, the few (5,6, 7,8-tetrahydro-naphthyl- (1) -oxypropyl] -piperazine derivatives described in German Offenlegungsschrift 2,235,597 possess antihypertensive and thus antihypertensive properties. the compounds according to the invention show no or only a low blood pressure lowering effect.

Framställningen av föreningarna enligt uppfinningen sker genom att man omsätter en förening med formeln cHo 3 o oï _ II _ __ 3 - _ o _H?5He med en förening med formeln F'\ z-N mig y * 111' . . \__/ vari Y och Z alltid är olika och antingen betecknar väte eller gruppen -CH2-CH(ORl)-CH2-V och V betecknar klor, brom eller iod eller kan om R betecknar väte tillsammans med denna hydroxigrupp l även bilda en etylenoxidring och att eventuellt en eller två nitro- grupper reduceras till aminogrupper och/eller att de erhållna föreningarna acyleras med en syra resp. ett syraderivat som motsvarar gruppen Rl. 780-3742-1 4 Förfarandet för framställning av föreningar enligt upp- finningen kan genomföras med eller utan lösningsmedel vid tempe- raturer mellan 20 till 200°C, företrädesvis 50 till ISOOC. Som läsnings- resp. dispergeringsmedel ifrågakommer exempelvis: aromatiska kolväten såsom exempelvis bensen, tohien eller xvlen; alifatiska ketoner såsom exempelvis aceton eller metvletvlketon; halogenerade kolväten såsom exempelvis kloroform, tetraklorkolväte, klorbensen eller metylenklorid; alifatiska etrar såsom exempelvis butyleter; cvkliska etrar såsom exempelvis tetrahvdrofuran eller dioxan; sulfoxider såsom exempelvis dimetylsulfoxid; tertiära syraamider såsom exempelvis dimetylformamid, N-metvlpyrrolidon; alifatiska alkoholer såsom metanol, etanol, isopropanol, amyl- alkohol eller tert.-butanol; cykloalifatiska kolväten såsom cvklo- hexan och liknanden. Även vattenhaltiga blandningar av de nämnda lösningsmedlen kan användas. Ofta arbetar man vid det använda lösnings- resp. dispergeringsmedlets återflödestemperatur.The compounds of the invention are prepared by reacting a compound of the formula cHo 3 o oï _ II _ __ 3 - _ o _H? 5He with a compound of the formula F '\ z-N mig y * 111'. . wherein Y and Z are always different and either represent hydrogen or the group -CH 2 -CH (OR 1) -CH 2 -V and V represents chlorine, bromine or iodine or if R represents hydrogen together with this hydroxy group 1 may also form an ethylene oxide ring and that optionally one or two nitro groups are reduced to amino groups and / or that the obtained compounds are acylated with an acid resp. an acid derivative corresponding to the group R1. 780-3742-1 4 The process for the preparation of compounds according to the invention can be carried out with or without solvent at temperatures between 20 to 200 ° C, preferably 50 to ISOOC. As a reading resp. dispersants include, for example: aromatic hydrocarbons such as benzene, tohien or xylene; aliphatic ketones such as acetone or methyl ethyl ketone; halogenated hydrocarbons such as, for example, chloroform, tetrachlorohydrocarbon, chlorobenzene or methylene chloride; aliphatic ethers such as butyl ether; cyclic ethers such as, for example, tetrahydrofuran or dioxane; sulfoxides such as, for example, dimethyl sulfoxide; tertiary acid amides such as, for example, dimethylformamide, N-methylpyrrolidone; aliphatic alcohols such as methanol, ethanol, isopropanol, amyl alcohol or tert-butanol; cycloaliphatic hydrocarbons such as cyclohexane and the like. Aqueous mixtures of the mentioned solvents can also be used. Often you work with the used solution resp. the reflux temperature of the dispersant.

I allmänhet omsättes reaktionskomponenterna i molära mängder.In general, the reactants are reacted in molar amounts.

Eventuellt kan det dock vara lämpligt att använda föreningen med formeln III om Z betecknar väte,i överskott (exempelvis 0,5 mol).However, it may be appropriate to use the compound of formula III if Z represents hydrogen, in excess (for example 0.5 mol).

Eventuellt kan omsättningen även genomföras i närvaro av syra- bindande medel såsom alkalikarbonater (pottaska, soda), alkali- hydroxider eller tert.-aminer (exempelvis trietylamin). Det senare gäller särskilt när föreningar användes vari V betecknar en halogen- atom.Optionally, the reaction can also be carried out in the presence of acid-binding agents such as alkali carbonates (potash, soda), alkali hydroxides or tert-amines (for example triethylamine). The latter is especially true when compounds are used in which V represents a halogen atom.

Om en förening med formeln II användes som utgångssubstans vari Y betecknar väte kan denna förening även användas i form av ett metallsalt, företrädesvis alkalisaltet (exempelvis natrium~ eller kaliumsaltet). Speciellt gäller detta när i den andra reaktionskomponenten III i gruppen Z = -CH2-CH(ORl)-CHZV symbolen V utgör en halogenatom.If a compound of formula II is used as the starting substance wherein Y represents hydrogen, this compound can also be used in the form of a metal salt, preferably the alkali metal salt (for example the sodium or potassium salt). This is especially true when in the second reactant III in the group Z = -CH 2 -CH (OR 1) -CH 2 V the symbol V is a halogen atom.

Vid genomförandet av reaktionen kan som etylenoxidutgångs- 'förening i stället för etylenoxidföreningen även motsvarande halogenhydrid eller en blandning av dessa båda föreningar (svntes- råprodukt) användas.In carrying out the reaction, the corresponding halogen hydride or a mixture of these two compounds (synthetic crude product) can also be used as the ethylene oxide starting compound instead of the ethylene oxide compound.

I de erhållna produkterna kan förefintliga amino- och/eller hydroxigrupper samt de mittstâende sekundära hvdroxiqrupperna (införing av Rl-acylgruppen) erhållas genom acylering, d v s behandling med syra med formeln RIOH varvid Rl förutom väte har an- giwmxteqfiblsecfller genom behandling med motsvarande reaktions- benägna syraderivat. I Som motsvarande svraderivat ifrågakommer särskilt föreningar 7803742-1 med formeln R W IV l vari W betecknar klor, brom eller jod, gruppen -NEN, en grupp med BH , -O-PO (OH) 2 , Härvid betecknar R' formel -OR', -SR' eller en grupp med formeln -OSO -OP(OR')2, -O-As(OR')2 eller -OCO-R". en alkylgrupp eller när grupperna -OR' resp. -SR' avses exempelvis även en fenylgrupp, p-nitrofenvlgrupp, cyanmetylgrupp eller karboximetylgrupp; R" kan beteckna en rak eller grenad alkvlgrupp, en alkoxigrupp, en fenoxigrupp, en karbobensoxigrupp eller även Även alifatiska ketener med 2 - 6 kolatomer kan användas Speciellt användes som acvleringsmedel sådana Om R' resten Rl. som acyleringsmedel. syraderivat med formeln IV vari W betecknar klor eller brom. resp. R" betecknar alkvl- eller alkoxigrupper är dessa företrädesvis lâgmolekvlära och har 1 - 6 kolatomer.In the products obtained, existing amino and / or hydroxy groups as well as the middle secondary hydroxy groups (introduction of the R1-acyl group) can be obtained by acylation, ie treatment with acid of the formula R10H, wherein R1 in addition to hydrogen has glycemic reactions by treatment with corresponding acid derivatives. As the corresponding derivative derivative, there are in particular compounds 7803742-1 of the formula RW IV 1 in which W represents chlorine, bromine or iodine, the group -NEN, a group with BH, -O-PO (OH) 2. Here, R represents 'formula -OR' , -SR 'or a group of the formula -OSO -OP (OR') 2, -O-As (OR ') 2 or -OCO-R ". An alkyl group or when the groups -OR' or -SR 'are meant e.g. also a phenyl group, p-nitrophenyl group, cyanomethyl group or carboxymethyl group; R "may denote a straight or branched alkyl group, an alkoxy group, a phenoxy group, a carbobenzoxy group or even Aliphatic ketenes having 2 to 6 carbon atoms may be used. the rest Rl. as acylating agent. acid derivatives of the formula IV wherein W represents chlorine or bromine. resp. R "denotes alkyl or alkoxy groups, these are preferably low molecular weight and have 1 to 6 carbon atoms.

Acyleringen kan exempelvis ske i inerta lösnings- resp. suspensionsmedel såsom vatten, lägre alifatiska alkoholer, lägre alifatiska ketoner, dioxan, dimetylformamid, bensen eller toluen vid temperaturer mellan 0 till 200OC. Eventuellt arbetar man under tillsats av ett syrabindande medel såsom alkalihydroxider, alkali- karbonater (kaliumkarbonat), alkalivätekarbonater, alkaliacetater, jordalkalikarbonater, tertiära aminer (exempelvis trialkylamin, pvridin) eller alkalialkoholater (natriumetylat). göra så att man först i den för omsättning avsedda föreningen överför grupperna som skall acvleras (hvdroxigrupper, aminogrupper) Man kan även i motsvarande alkaliförening, genom att man omsätter dem i ett inert lösningsmedel såsom dioxan, dimetylformamid, bensen eller toluen med en alkalimetall, alkalihvdrid eller alkaliamid (speciellt naufium eller natriumföreningar) vid temperaturer mellan 0 och l50°C och tillsätter det acylerande medlet.The acylation can, for example, take place in inert solution resp. suspending agents such as water, lower aliphatic alcohols, lower aliphatic ketones, dioxane, dimethylformamide, benzene or toluene at temperatures between 0 to 200 ° C. Optionally, the reaction is carried out with the addition of an acid-binding agent such as alkali hydroxides, alkali metal carbonates (potassium carbonate), alkali metal bicarbonates, alkali metal acetates, alkaline earth carbonates, tertiary amines (for example trialkylamine, pyridine) or alkali alcoholates (sodium ethylate). The groups to be acylated (hydroxy groups, amino groups) can also be transferred first in the compound to be reacted. The corresponding alkali compound can also be reacted by reacting them in an inert solvent such as dioxane, dimethylformamide, benzene or toluene with an alkali metal, alkali metal hydride. or alkali amide (especially sodium or sodium compounds) at temperatures between 0 and 150 ° C and add the acylating agent.

Om den fria syran med formeln RIOH användes erfordras akti- vering av denna genom närvaron av kondensationsmedel såsom dicyklo- hexvlkarbodiimid, svavelsyrlighet-bis-alkylamider (exempelvis SO:§(CH3)å_2), N,N'-karbonyldiimidazol osv. (Organic Reactions, volym 12, 1962, sidorna 205 och 239).If the free acid of the formula RIOH is used, its activation is required by the presence of condensing agents such as dicyclohexylcarbodiimide, sulfuric acid bis-alkylamides (for example SO: § (CH3) å_2), N, N'-carbonyldiimidazole and so on. (Organic Reactions, Volume 12, 1962, pages 205 and 239).

I stället för detangivnn acvleringsmedlet kan även andra inom kemin vanliga kemiska ckvivalenta medel användas-(exemnelvis även L.F. och Mary Fieser "Reagents for Organic Synthesis", John 1967, volym 1, sidorna 1303 - 4 Naturligtvis kan i de erhållna före- Wiley and Sons, Inc. New York, och volvm 2, sidorna 471). ningarna förefintliqa acvlgrupper på känt sätt även åter avspjälkas, exempelvis med vattenhaltig alkali eller alkoholhaltig alkalihvdroxid 7303742-1 6 (exempelvis metanolisk KOH) eller eventuellt även med mineralsvror såsom saltsyra eller svavelsyra i alkoholisk eller vatten-alkohol- lösning vid temperaturer mellan 20 och l00°C.Instead of the above-mentioned builder, other chemical equivalents commonly used in chemistry can also be used- (e.g. also LF and Mary Fieser "Reagents for Organic Synthesis", John 1967, volume 1, pages 1303 - 4 Of course, in the obtained pre- Wiley and Sons , Inc. New York, and volvm 2, pages 471). the acyl groups present in a known manner are also cleaved again, for example with aqueous alkali or alcoholic alkali hydroxide (for example methanolic KOH) or possibly also with mineral acids such as hydrochloric acid or sulfuric acid in alcoholic or water-alcohol solution at temperatures between 20 and 100 ° C.

För reduktion av en eller även två nitrcgrupper ifrågakommer särskilt katalytisk hydrering. Som katalysatorer ifrågakommer exempelvis: raneynickel,ädelmetaller såsom palladium och platina samt föreningar därav med eller utan bärare såsom exempelvis barium- sulfat, kalciumsulfat osv. Det kan vara lämpligt att genomföra hydreringen av nitrogrupperna vid temperaturer mellan 20 och 80°C och ett tryck av ungefär 5 - 50 atö i ett lösningsmedel, exempelvis alkoholer, dioxan, tetrahydrofuran osv. För den efterföljande isoleringen av de reducerade föreningarna kan det i många fall Vara fördelaktigt att till att börja med till den hydrerande blandningen tillsätta torkningsmedel såsom vattenfritt natrium- eller magnesium- sulfat.For the reduction of one or even two nitrogen groups, catalytic hydrogenation is particularly important. Examples of catalysts are: raney nickel, precious metals such as palladium and platinum and compounds thereof with or without carriers such as, for example, barium sulphate, calcium sulphate, etc. It may be convenient to carry out the hydrogenation of the nitro groups at temperatures between 20 and 80 ° C and a pressure of about 5 to 50 atm in a solvent, for example alcohols, dioxane, tetrahydrofuran, etc. For the subsequent isolation of the reduced compounds, it can in many cases be advantageous to initially add drying agents to the hydrogenating mixture, such as anhydrous sodium or magnesium sulphate.

Reduktionen kan emellertid även ske med atomärt väte, _exempelvis zink/saltsyra, tenn/saltsvra, iärn/saltsyra eller med salter med svavelväte i alkohol/vatten vid ungefär 70 - l20°C eller med aktiverat aluminium i vattenhaltig eter vid 20 - 40°C eller med tenn(II)-klorid/saltsyra.However, the reduction can also be carried out with atomic hydrogen, for example zinc / hydrochloric acid, tin / hydrochloric acid, iron / hydrochloric acid or with salts with hydrogen sulphide in alcohol / water at about 70-120 ° C or with activated aluminum in aqueous ether at 20-40 ° C. or with stannous chloride / hydrochloric acid.

Föreningarna enligt uppfinningen kan i allmänhet erhållas som racemat. De optiskt aktiva antipoderna erhåller man antingen genom användning av optiskt aktiva utgångsämnen eller genom racematspjälkning över salter av optiskt aktiva syror såsom exempel- vis: L-(+)-vinsyra, D-(-)-vinsyra, (+)-0,0'-dibensoyl-D-vinsvra, (-)-0,0'-dibensoyl-L-vinsyra, (-9-0,0'-di-p-tolyovl-L-vinsvra, (+)-0,0'-di-p-toluoyl-D-vinsyra, (+)-kamfer-10-sulfonsyra och andra.The compounds of the invention can generally be obtained as racemates. The optically active antipodes are obtained either by using optically active starting materials or by racemic cleavage over salts of optically active acids such as, for example: L - (+) - tartaric acid, D - (-) - tartaric acid, (+) - 0.0 '-dibenzoyl-D-tartaric acid, (-) - 0,0'-dibenzoyl-L-tartaric acid, (-9-0,0'-di-p-tolyloyl-L-tartaric acid, (+) - 0,0' -di-p-toluoyl-D-tartaric acid, (+) - camphor-10-sulfonic acid and others.

Z Föreningarna med den allmänna formeln I kan enligt kända metoder överföras i salterna. Som anjoner för dessas salter ifråga- kommer kända och terapevtiskt användbara syrarester. Exempel på sådana syror är: HZSO4, fosforsyra, halogenvätesyra, etylendiamin- tetraättiksyra, sulfaminsvra, bensensulfonsyra, p-toluensulfonsyra, kamfersulfonsvra, metansulfonsyra, guajazulensulfonsvra, maleinsvra, fumarsyra, bärnstensyra, vinsyra, mjölksyra, askorbinsyra, qlykolsyra, salicylsvra, ättiksyra, propionsyra, glukonsyra, bensoesyra, citronsyra, acetaminoäflfiksvra och oxietansulfonsyra.Z The compounds of general formula I can be converted into the salts according to known methods. As anions for their salts, there are known and therapeutically useful acid residues. Examples of such acids are: H 2 SO 4, phosphoric acid, hydrohalic acid, ethylenediaminetetraacetic acid, sulfamic acid, benzenesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, methanesulfonic acid, guajazulensulfonic acid, maleic acid, fumaric acid, tartaric acid, tartaric acid, tartaric acid gluconic acid, benzoic acid, citric acid, acetaminoacetic acid and oxyethanesulfonic acid.

Av salterna av föreningarna kan på sedvanligt sätt åter de fria baserna framställas, exempelvis genom behandling av en lösning med ett organiskt medel såsom alkoholer (metanol) med soda eller natriumhydroxid. v 7863742-1 Beredningen enligt uppfinningen lämpar sig för framställning av farmacevtiska beredningar. De farmacevtiska beredningarna resp. medicinerna kan innehålla en eller flera föreningar enligt uppfin- ningen eller även blandningar av dessa med andra farmacevtiskt verksamma substanser. För framställning av de farmacevtiska bered- ningarna kan sedvanliga farmacevtiska bärare och hjälpsubstanser användas. Läkemedlen kan användas enteralt, parenteralt, oral: eller perlingualt. Exempelvis kan doseringen ske i form av tabletter, kapslar, piller, dragêer, suppositoria, salvor, gelër. creme, puder, vätskor, ströpulver eller aerosoler. Som vätskor ifrågakommer exempelvis: olje- eller vattenlösningar eller suspen- sioner, emulsioner, injicerbara vatten- och olielösningar eller suspensioner.From the salts of the compounds, the free bases can be prepared in the usual way, for example by treating a solution with an organic agent such as alcohols (methanol) with soda or sodium hydroxide. The composition according to the invention is suitable for the preparation of pharmaceutical preparations. The pharmaceutical preparations resp. the medicaments may contain one or more compounds according to the invention or even mixtures thereof with other pharmaceutically active substances. For the preparation of the pharmaceutical preparations, customary pharmaceutical carriers and excipients can be used. The drugs can be used enterally, parenterally, orally: or perlingually. For example, the dosage may be in the form of tablets, capsules, pills, dragees, suppositories, ointments, gels. creams, powders, liquids, powders or aerosols. Suitable liquids are, for example: oil or water solutions or suspensions, emulsions, injectable water and oil solutions or suspensions.

Utgångsföreningarna med formeln III vari Z betecknar gruppen -CH2-CH(0H)-CH2-V, kann exempelvis erhållas på sedvanligt sätt genom omsättning av epiklor- resp. epibromhydrin med motsvarande piperazin som innehåller gruppen R2 i 4-ställning, i alkohol, företrädesvis metanol under tillsats av ungefär 5 % vatten vid l0°C. Reaktionstiden uppgår~exempelvis till en halvtimme.The starting compounds of the formula III in which Z represents the group -CH2-CH (OH) -CH2-V, can be obtained, for example, in the usual manner by reaction of epichloro- or epibromohydrin with the corresponding piperazine containing the group R 2 in the 4-position, in alcohol, preferably methanol with the addition of about 5% water at 10 ° C. The reaction time is ~, for example, half an hour.

Därefter upphettar man till 30 - 400 och omrör 5 timmar.Then heat to 30 - 400 and stir for 5 hours.

Förhållandet piperazin till hydrin uppgår exempelvis till lzl - 1:5, företrädesvis 1:1 - 1:2. Vattenhalten kan även ligga mellan l och l0 %, företrädesvis 2 och 6 %.The ratio of piperazine to hydrin is, for example, 1z1 - 1: 5, preferably 1: 1 - 1: 2. The water content can also be between 1 and 10%, preferably 2 and 6%.

I de så erhållna föreningarna kan genom acylering med en förening Rlw under de redan angivna betingelserna gruppen Rl införas. På samma sätt kan även-Rl införas i utgångsföreningarna med formeln II vari Y betecknar gruppen -CH2-CH(OH)-CH2-V.In the compounds thus obtained, the group R1 can be introduced by acylation with a compound R1w under the conditions already given. Similarly, R 1 may also be introduced into the starting compounds of formula II wherein Y represents the group -CH 2 -CH (OH) -CH 2 -V.

De övriga utgångsföreningarna är kända.The other starting compounds are known.

Uppfinningen åskâdliggöres närmare medelst följande exempel vari temperaturerna avser CO.The invention is further illustrated by the following examples in which the temperatures refer to CO.

Exempel l. (É)-l-:É-(3,4,5-trimetoxifenoxi)-2-hvdroxi-propylj-4-(2- metoxifenyl)-piperazin. 12 g (0,05 mol) 3,4,5-trimetoxifenoxi-glycidvleter kokades med 9,6 g (0,05 mol) 1-(2-metoxifenyl)-piperazin i 100 ml iso- propanol 5 timmar under återflöde. Därefter avdestillerades den största delen av lösningsmedlet och återstoden behandlades med ett överskott isopropanolhaltig HCI och dihvdrokloriden av l~:3~(3,4,5- trimetoxifenoxi)-2-hvdroxi-propyíï-4-(2-metoxifenvl)-piperazin utfälldes genom tillsats av dietyleter. Man erhöll l8,4 g (73 3 av det teoretiska) som färglös kristallin substans, smältpunkt för 7803742-1 8 ainydrekleriaen 196 - 197°. 3,4,5-trimetoxifenoxiglycidyletern kan exempelvis framställas på följande sätt: I ett lämpat reaktionskärl med en anordning för azeotrop vattenavskiljning upphettades 18,4 g (0,1 mol) 3,4,5-trimetoxifenol med 37 g (0,4 mol) epiklorhvdrin till kokning och inom 30 minuter tilldroppades l0 g (0,1 mol) 40-procentig natriumhydroxid varvid samtidigt vattnet avskiljdes azeotropt. Efter avslutad tillsats av natriumhydroxiden lät man blandningen efterreagera en timme vid koktemperatur, spådde med ca l00 ml toluen och avfiltrerade utskild NaCl. Filtratet fraktionerades först under normaltrvck, därefter i vakuum. 3,4,5-trimetoxifenoxiglycidyletern erhölls vid kpl'0 = 175 - 1so°c sem färglös ene; utbyte: 19,2 g motsvarande 80 % utbyte, beräknat på trimetoxifenolen.Example 1. (E) -1-: E- (3,4,5-Trimethoxyphenoxy) -2-hydroxy-propyl-4- (2-methoxyphenyl) -piperazine. 12 g (0.05 mol) of 3,4,5-trimethoxyphenoxy-glycidyl ether were boiled with 9.6 g (0.05 mol) of 1- (2-methoxyphenyl) -piperazine in 100 ml of isopropanol for 5 hours under reflux. Then most of the solvent was distilled off and the residue was treated with an excess of isopropanol-containing HCl and the dihydrochloride of 1: 3- (3,4,5-trimethoxyphenoxy) -2-hydroxy-propyl-4- (2-methoxyphenyl) -piperazine was precipitated by addition of diethyl ether. 18.4 g (73% of theory) were obtained as a colorless crystalline substance, m.p. 196 DEG-197 DEG. The 3,4,5-trimethoxyphenoxy glycidyl ether can be prepared, for example, as follows: In a suitable reaction vessel with an azeotropic water separation device, 18.4 g (0.1 mol) of 3,4,5-trimethoxyphenol were heated with 37 g (0.4 mol). epichlorohydrin to boiling and within 30 minutes 10 g (0.1 mol) of 40% sodium hydroxide were added dropwise, at the same time the water was separated azeotropically. After the addition of the sodium hydroxide was completed, the mixture was allowed to react for one hour at boiling temperature, diluted with about 100 ml of toluene and filtered off separated NaCl. The filtrate was fractionated first under normal pressure, then in vacuo. The 3,4,5-trimethoxyphenoxyglycidyl ether was obtained at kp1'0 = 175-150 ° C as a colorless one; yield: 19.2 g corresponding to 80% yield, calculated on the trimethoxyphenol.

Förfarandet förframställning av förfarandeprodukten kan även ske på följande sätt: 0,05 mol natrium-(3,4,5-trimetoxi)-fenolat upphettades med 0,05 mol l-(3~klor-2-hydroxi-propyl)-4-(2-metoxifenyl)-piperazin (framställd genom omsättning av l-(2~metoxifenyl}piperazin med epiklorhydrin)-i 50 ml dioxan,8 timmar under återflöde,till kokning.The process Preparation of the process product can also be carried out as follows: 0.05 mol of sodium (3,4,5-trimethoxy) phenolate was heated with 0.05 mol of 1- (3-chloro-2-hydroxy-propyl) -4- (2-methoxyphenyl) -piperazine (prepared by reacting 1- (2-methoxyphenyl} piperazine with epichlorohydrin) in 50 ml of dioxane, 8 hours under reflux, until boiling.

Efter avkylning avfiltrerades utfallen NaCl och filtratet induns- tades. Återstoden behandlades med isopropanolhaltig saltsvra och otcr och den kristallina fasta substansen omkristalliserades ur metanol. Man erhöll 8,2 g (32 % av det teoretiska) (i)-l-:§- (3,4,5-trimetoxifenoxi)-2-hydroxi-propyl:-4-(2-metoxifenyl)- piperazin som dihydroklorid med smältpunkt l94 - 1960.After cooling, the precipitated NaCl was filtered off and the filtrate was evaporated. The residue was treated with isopropanol-containing hydrochloric acid and otcr and the crystalline solid was recrystallized from methanol. 8.2 g (32% of theory) of (i) -1-: §- (3,4,5-trimethoxyphenoxy) -2-hydroxy-propyl: -4- (2-methoxyphenyl) -piperazine were obtained as dihydrochloride with melting point l94 - 1960.

En annan möjlighet att genomföra förfarandet är följande: En blandning av 0,05 mol 3-(3,4,5 -trimetoxifenoxi)-2- hydroxi-propylbromid, 0,05 mol l-(2-metoxifenyl)-piperazin och 0,06 mol trietylamin upphettades i 100 ml toluen 5 timmar under återflöde till kokning. Därefter avfiltrerades den utfallande trietylammoniumbromiden och filtratet indunstades. Återstoden upptogs i en liten mängd isopropanol och med isopropanolhaltig saltsvra och eter utfälldes dihydrokloriden av (f)-l-:š-(3,4,5- trimetoxifenoxi)-2~hvdroxi-propyi:-4-(2-metoxifenvl)-piperazin.Another possibility of carrying out the process is as follows: A mixture of 0.05 moles of 3- (3,4,5-trimethoxyphenoxy) -2-hydroxy-propyl bromide, 0.05 moles of 1- (2-methoxyphenyl) -piperazine and 0, 06 moles of triethylamine were heated in 100 ml of toluene for 5 hours under reflux to boiling. Then the precipitated triethylammonium bromide was filtered off and the filtrate was evaporated. The residue was taken up in a small amount of isopropanol and with isopropanol-containing hydrochloric acid and ether the dihydrochloride precipitated from (f) -1-: š- (3,4,5-trimethoxyphenoxy) -2-hydroxy-propyl: -4- (2-methoxyphenyl) - piperazine.

Man erhöll efter omkristallisation ur metanol l0,l g av den rena föreningen (40 a av det teoretiska), emäitpunkt 195 - 197°.After recrystallization from methanol, 1.0 g of the pure compound (40 .mu.l of theory) were obtained, m.p. 195 DEG-197 DEG.

På analogt sätt som i första avsnittet av exempel l erhölls ur vardera 0,05 mol 3,4,5-trimetoxifenoxiglvcidyleter och 0,05 mol av en förening med formeln III de i tabell l angivna föreningarna med formeln 9 78613742-.1 CHBO /--\ ca o o - (m2 - cH(oH) - C112 - N _ N-nz Exemoel 22. (i)-l-[3-(3,4,5-trimetoxifenoxi)-2-(nikotinoyloxi)-propyl]- 4-(2-metoxifenyl)-piperazin 13,0 g (o,o3 moi) (in-1-B-(afns-trimetogifenoxi)-z-nyaroxi- propy:]-4-(2-metoxifenyl)-piperazin löstes tillsammans med 3,34 g trietylamin (0,033 mol) i 80 ml vattenfri bensen och försattes inom 30 minuter med en lösning av 4,67 g (0,033 mol) nikotinsyraklorid i 50 ml vattenfri bensen. Man efterrörde ytterligare 2 timmar vid rumstemperatur och upphettade slutligen blandningen ytterligare en timme till 70 - 800. Efter avkylning utskakades blandningen flera gånger med vatten, eftertvättades med vattenhaltig NaHC03 och vatten och den bensenhaltiga fasen torkades med magnesiumsulfat och indunstades. Den fasta återstoden upptogs i dioxan. Efter tillsats av överskott isopropanolhaltig saltsyra och eter erhöll man 13,0 g (67 % av det teoretiska) av den ovan nämnda föreningen som trihydroklorid (färglösa kristaller). Smältpunkt 187 - 1920 (sönderdelning).In an analogous manner to the first section of Example 1, from each of the 0,05 moles of 3,4,5-trimethoxyphenoxyglycidyl ether and 0,05 moles of a compound of formula III were obtained the compounds of the formula 9 listed in Table 1. - \ ca oo - (m2 - cH (oH) - C112 - N _ N-nz Example 22. (i) -1- [3- (3,4,5-trimethoxyphenoxy) -2- (nicotinoyloxy) -propyl ] - 4- (2-methoxyphenyl) -piperazine 13.0 g (o, o3 moi) (in-1-β- (β-trimethogyphenoxy) -z-nyaroxypropyl:] - 4- (2-methoxyphenyl) - piperazine was dissolved together with 3.34 g of triethylamine (0.033 mol) in 80 ml of anhydrous benzene and added within 30 minutes to a solution of 4.67 g (0.033 mol) of nicotinic acid chloride in 50 ml of anhydrous benzene, stirring for a further 2 hours at room temperature and finally heated the mixture for another hour to 70-800. After cooling, the mixture was shaken several times with water, washed with aqueous NaHCO 3 and water and the benzene-containing phase was dried over magnesium sulphate and evaporated. and dioxane. After addition of excess isopropanolic hydrochloric acid and ether, 13.0 g (67% of theory) of the above compound were obtained as trihydrochloride (colorless crystals). Melting point 187 - 1920 (decomposition).

Exemoel 23. (ï)-l-E§-[§,4,5-trimetoxifenoxi:-2-:B,4,5 -trimetoxi- bensoyoxi:-propyiâ-4-(2-metoxifenyl)-piperazin (i) -1- I: 3- ( 3 , 4 , s-trimetoxifenoxn -z-hydroxi-propyfi -4- (2- metoxifenyl)-piperazin omsattes analogt med exempel 20 med 3,4,5- trimetoxibensoylklorid i närvaro av trietylamin. Reaktionsprodukten erhöll man som dihydroklorid, smältpunkt 193 - 1950 (sönderdelning).Example 23. (ï) -1E§- [§, 4,5-trimethoxyphenoxy: -2-: B, 4,5-trimethoxybenzooxy: -propyl] -4- (2-methoxyphenyl) -piperazine (i) -1 I: 3- (3,4,4-Trimethoxyphenoxine-2-hydroxy-propyl-4- (2-methoxyphenyl) -piperazine was reacted analogously to Example 20 with 3,4,5-trimethoxybenzoyl chloride in the presence of triethylamine. as dihydrochloride, m.p. 193 - 1950 (decomposition).

Utbyte 38 å.Yield 38 å.

Exemoel 24. (i)-l-:§-(3,4,5~trimetoxifenoxi)-2-hydroxipropyí:-4-(2- acetamidofenyl)-piperazin 4 g (ï)-l-[§-(3,4,5-trimetoxifenoxi-2-hydroxipropyiï-4-(2- aminofenyl)-piperazin (monohydroklorid) löstes i 2Ö0 ml dioxan och försattes med 10 ml trietylamin. Därefter tilldroppade man under omrörning vid -50 0,9 ml acetylklorid. Efter 2 timmars efter- reaktion vid rumstemperatur filtrerades lösningen och lösnings~ medlet avlägsnades under förminskat trvck. Genom torrkolonnkroma- 10 @H~oHxoHw>:fl@ ^** UflH0HMon¶>J0:0=~ A* mm ^* æmp H>cwwoHuflc|N :flNmHmmfim|^fi>Gwm0HuH:|Nv|~ FN Fw ^mømv -np Hæcmuflxonwæslm cflwmumßflmx^fi>cwmflN0nwwnïNv|P ON N: ^**:ww.| www ^wv|H>wflu>m cflNmHwQfl@|^wV|H>wfi~>m|P mp.Example 24. (i) -1-: §- (3,4,5-trimethoxyphenoxy) -2-hydroxypropyl: -4- (2-acetamidophenyl) -piperazine 4 g (ï) -1- [§- (3, 4,5-Trimethoxyphenoxy-2-hydroxypropyl-4- (2-aminophenyl) -piperazine (monohydrochloride) was dissolved in 20 ml of dioxane and added with 10 ml of triethylamine, then added dropwise with stirring at -50 0.9 ml of acetyl chloride. hours after-reaction at room temperature, the solution was filtered and the solvent was removed under reduced pressure.Through column column chroma- 10 @ H ~ oHxoHw>: fl @ ^ ** U fl H0HMon¶> J0: 0 = ~ A * mm ^ * æmp H> cwwoHu fl c | N: fl NmHmm fi m | ^ fi> Gwm0HuH: | Nv | ~ FN Fw ^ mømv -np Hæcmu fl xonwæslm c fl wmumß fl mx ^ fi> cwm fl N0nwwnïNv | P ON N: ^ **: ww. | Www fl nw | m ^ | wV | H> w fi ~> m | P mp.

Pw ^*n:N | Næm ^Hvwfi>ummc QflNmummflm|^Hv|H>ummc|_ w- mw ^**NhF I mwp H>cmwHw#wEH0damflnu|fi nflNmHwmfim|^H>:mmH>uoEu0øfimfiuuïnv|v NP wn ^*wow | now H>=wwH>@weHo=HwH~u|w . øflwmuwmflml^H>=«wH>wwa»oøH«flHw|wv|- w, Ammmv . mn wfip I ßnw H>nwmHæ#w0m\: sfiwmHmmHQ|Afibømmfinumomtavlw mfi Fb ^*OfiN.| mmm H>cwmH>umEflw|w.N cflwmnmmflßl^H>cmmH>uwEflU|m.mvlfi av om ^**ww. | wwp H>cmwH>»waflø|«.n nflwmuwmflmn^~>nwwH>»waHw1w.nv|_. n. ww ^**wm,_| www H>=w«H>»we|n .wcfiwm~wmfi@|^H>=wwfi>pws|nv|_ w. .rm ^*mmP | mm- Hmcmmflwuwëlm Qflmmnmmwml^H>nmwflæwoE|Nv|~ P- mw Åämwf | nw~ Hæ:wwOumduHwEH>umE|N cflwmummflml^HMGwmoumm0nmEH>uwE|NvI~ O» mcfisfimwnwwsæm :w ^**øoN I wav fl>cmmflx0um|m :fiwmuwmflm|^H>:0Mflxouw|flv|- m :N ^**0PN I mom H>:wwflxouwET: cflwmnmmflQ|^H>c@wflNOuwE|:v|P w mm ^**:oN | mom H>nwmHxouoE|n cflwmu@Qfim|^H>cmmflxouwE|nv|~ N av &**POm | am, H>cmmnOHx|: cflwmH®mfim¿H>:mmHoHM|:v|~ w ww ^*fiNF l NN- H>cmmH0HM|fl cflumnwcflßn^fl>GwMn0HM|nv|- M ww ^*nmF 1 mm, H>=wwHoHx|w sfiwmnwmfl@|^H>ø@«HoHM|wv|F z nu ^:xn0N | Now Hæcwwuoøflmne cflwmnøafiml^H>nmmH0øHw|:v|F G mw ^**mæ_ 1 >æ_ H>:@w qfiwm~wmHmfi>=ww|_ w mxmfiuanoow o o . _ now >m & Hwäuou HHH sfiwëncw wmí ac .o~>J@D. Qxcsluflmëm 0vswwuwcm>O A Nå a:a:02E3zwm:mauu _HQæÜmq . 1sez142-1 OH F fifiwßdà H 7803742~1 tografi på kiselgel (elutionsmedel åter-etvïàëÉtat'å 151) išblèrades den önskade föreningen. Omkristallisation skedde ur aceton-eter. utbyte: so %. smältpunkt 128 - 13o°.Pw ^ * n: N | Næm ^ Hvw fi> ummc Q fl Nmumm fl m | ^ Hv | H> ummc | _ w- mw ^ ** NhF I mwp H> cmwHw # wEH0dam fl nu | fi n fl NmHwm fi m | ^ H>: mmH> uoEu0ø fi m fi uuïnv | now H> = wwH> @ weHo = HwH ~ u | w. ø fl wmuwm fl ml ^ H> = «wH> wwa» oøH «fl Hw | wv | - w, Ammmv. mn w fi p I ßnw H> nwmHæ # w0m \: s fi wmHmmHQ | A fi bømm fi numomtavlw m fi Fb ^ * O fi N. | mmm H> cwmH> umE fl w | w.N c fl wmnmm fl ßl ^ H> cmmH> uwE fl U | m.mvl fi av om ^ ** ww. | wwp H> cmwH> »wa fl ø |« .n n fl wmuwm fl mn ^ ~> nwwH> »waHw1w.nv | _. n. ww ^ ** wm, _ | www H> = w «H>» we | n .wc fi wm ~ wm fi @ | ^ H> = ww fi> pws | nv | _ w. .rm ^ * mmP | mm- Hmcmm fl wuwëlm Q fl mmnmmwml ^ H> nmw fl æwoE | Nv | ~ P- mw Åämwf | nw ~ Hæ: wwOumduHwEH> umE | N c fl wmumm fl ml ^ HMGwmoumm0nmEH> uwE | NvI ~ O »mc fi s fi mwnwwsæm: w ^ ** øoN I wav fl> cmm fl x0um | m: fi wmuwm fl m | | M | * 0PN I mom H>: ww fl xouwET: c fl wmnmm fl Q | ^ H> c @ w fl NOuwE |: v | P w mm ^ **: oN | mom H> nwmHxouoE | n c fl wmu @ Q fi m | ^ H> cmm fl xouwE | nv | ~ N av & ** POm | am, H> cmmnOHx |: c fl wmH®m fi m¿H>: mmHoHM |: v | ~ w ww ^ * fi NF l NN- H> cmmH0HM | fl c fl umnwc fl ßn ^ fl> GwMn0HM | nv | - M ww ^ * nmF 1 mm H> = wwHoHx | w s fi wmnwm fl @ | ^ H> ø @ «HoHM | wv | F z nu ^: xn0N | Now Hæcwwuoø fl mne c fl wmnøa fi ml ^ H> nmmH0øHw |: v | F G mw ^ ** mæ_ 1> æ_ H>: @ w q fi wm ~ wmHm fi> = ww | _ w mxm fi uanoow o o. _ now> m & Hwäuou HHH s fi wëncw wmí ac .o ~> J @ D. Qxcslu fl mëm 0vswwuwcm> O A Nå a: a: 02E3zwm: mauu _HQæÜmq. 1sez142-1 OH F fifi wßdà H 7803742 ~ 1 topography on silica gel (eluent re-etvïàëÉtat'å 151) išblèrades the desired compound. Recrystallization was from acetone-ether. yield: so%. melting point 128 - 130 °.

Som en mindre polär biprodukt, som genom att öka acetyl- kloridmängden kan erhållas som huvudprodukt erhölls (t)-l-[§-(3,4,5- trimetoxifencxi)~2~acetoxipropyl]-4-(2-acetamidofenvl)-piperazin.As a less polar by-product, which by increasing the amount of acetyl chloride can be obtained as the main product, (t) -1- [§- (3,4,5-trimethoxyphenoxy) -2-acetoxypropyl] -4- (2-acetamidophenyl) - piperazine.

Smältpunkt 540.Melting point 540.

Exemgel 25. (-)-l-E§-(3,4,5-trimetoxifenoxi)-2-acetoxipropyl]-4-(2- acetoxifenyl)-piperazin 6 g (o,o143 moi) (ï)-1~[;-(3,4,s-tr1met°xifen°xi)-2- hydroxipropyí]-4-(2-hydroxifenyl)-piperazin och 2,9 g (0,0286 mol) trietylamin löstes i 80 ml absolut metylenklorid och försattes vid 0° droppvis med en lösning av 2,24 g (0,0286 mol) acetylklorid i 20 ml absolut metylenklorid. Reaktionsblandningen omrördes 2 timmar vid rumstemperatur och den utfallande trietylaminhydrokloriden avfiltrerades. Därefter avdestillerades lösningsmedlet i vakuum och återstoden omkristalliserades ur eter/petrolumeter. Utbyte: 57 %, smältpunkt 700.Example Gel 25. (-) - 1E§- (3,4,5-trimethoxyphenoxy) -2-acetoxypropyl] -4- (2-acetoxyphenyl) -piperazine 6 g (0,143 moi) (ï) -1 ~ [; - (3,4,5-S-trifluoromethylphenyl) -2-hydroxypropyl] -4- (2-hydroxyphenyl) -piperazine and 2.9 g (0.0286 mol) of triethylamine were dissolved in 80 ml of absolute methylene chloride and added to 0 ° dropwise with a solution of 2.24 g (0.0286 mol) of acetyl chloride in 20 ml of absolute methylene chloride. The reaction mixture was stirred for 2 hours at room temperature and the precipitated triethylamine hydrochloride was filtered off. Then the solvent was distilled off in vacuo and the residue was recrystallized from ether / petroleum ether. Yield: 57%, melting point 700.

Exemgel 26.~ (i)-l-[§r(3,4,5-trimetoxifenoxi)-2-hydroxipropyí]-4-(2- aminofenyl)-piperazin 6 g (0,0l24 mol) (i)-l-E?-(3,4,5-trimetoxifenoxi)-2-hydroxi- propyâ]-4-(2-nitrofenyl)-piperazin löstes i 300 ml metanol och hydrerades i närvaro av 0,5 g Pd-C (10-procentig) vid rumstempe- ratur. Efter avfiltrering av katalysatorn och efter att ha avlägsnat lösningsmedlet i vakuum omkristalliserades produkten ur etanol. Utbyte: 94 %. Smältpunkt för monohydrokloridenz 181 - 1s3°.Example Gel 26. - (i) -1- [[(3,4,5-trimethoxyphenoxy) -2-hydroxypropyl] -4- (2-aminophenyl) -piperazine 6 g (0.0124 mol) (i) -1E ? - (3,4,5-Trimethoxyphenoxy) -2-hydroxypropyl] -4- (2-nitrophenyl) -piperazine was dissolved in 300 ml of methanol and hydrogenated in the presence of 0.5 g of Pd-C (10%). at room temperature. After filtering off the catalyst and removing the solvent in vacuo, the product was recrystallized from ethanol. Yield: 94%. Melting point of monohydrochloridenz 181 - 1s3 °.

Exempel pär racematspjälkning (+)-1-[i3-(3,4,5-trimeuoxifenoxi)-2-nyaroxipropyi]-4-(2- metoxifenyl)fpiperazin (bas = förening la) och (-)-l-[§-(3,4,5-trimetoxifenoxi)-2-hydroxipropvll-4-(2-metoxi- fenyl)-piperazin (bas = förening lb). 4,32 g (0,005 mol) av den enligt exempel 1 framställda racemiska föreningen löstes varm i 80 ml butylacetat och vid 800 tillsattes portionsvis under kraftig omrörning 4,04 9 (0,005 mol) -(-)-di-p-toluoyl-L-vinsyrahydrat varvid det vänstervridande diastereomera saltparet utfälldes. Man upphettade därefter ytterligare io minuter till 11o°, lät blandning kylas till ao° och avfiltrerade fällningen. Saltparet omkristalliserades ur 1so3742-1 of i f¿ aceton-dimetylformamid-bensin (EÄJ 20 - 48,60; l % i dimetyl- D formamid) och avspjälkades därefter genom behandling med koncent- rerad ammoniak. Basenextraherades med eter ochqamraktet indunstades.Examples of racemate cleavage (+) - 1- [1-3 (3,4,5-trimeaoxyphenoxy) -2-nyaroxypropyl] -4- (2-methoxyphenyl) piperazine (base = compound 1a) and (-) - 1- [§ - (3,4,5-trimethoxyphenoxy) -2-hydroxypropyl-4- (2-methoxyphenyl) -piperazine (base = compound 1b). 4.32 g (0.005 mol) of the racemic compound prepared according to Example 1 were dissolved hot in 80 ml of butyl acetate and at 800 4.04 g (0.005 mol) - (-) - di-p-toluoyl-L were added portionwise with vigorous stirring. tartaric hydrate whereby the left-handed diastereomeric salt pair precipitated. The mixture was then heated to 110 DEG C. for a further 10 minutes, the mixture was allowed to cool to 100 DEG C. and the precipitate was filtered off. The salt pair was recrystallized from 50 DEG-374 DEG C. in acetone-dimethylformamide-gasoline (EAJ 20-48.60; 1% in dimethyl-D-formamide) and then cleaved by treatment with concentrated ammonia. Base was extracted with ether and the crucible was evaporated.

Den fasta återstoden omkristalliserades ur isopropanol; la-bas färglös kristall, smältpunkt 103 - l04°; EQQJ :O + 7,20 (koncent- ration i 2 % i CH3OH). Genom att lösa basen 1 metanol och försätta med isopropanolhaltig saltsyra och eter erhöll man dihydrokloriden av föreningen la i form av färglösa kristaller, smältpunkt 189 - 193°; E¿[{š° - 11,4° (koncentration = 2 % 1 cn3on).The solid residue was recrystallized from isopropanol; 1a-base colorless crystal, m.p. 103 DEG-104 DEG; EQQJ: O + 7.20 (concentration in 2% in CH 3 OH). By dissolving the base in methanol and adding isopropanol-containing hydrochloric acid and ether, the dihydrochloride of the compound Ia was obtained in the form of colorless crystals, m.p. 189-193 °; E¿ [{š ° - 11.4 ° (concentration = 2% 1 cn3on).

Filtratet av saltparfällningen, som innehöll det höger- vridande diastereomera saltparet indunstades vid rotationsinduns- tare, den visköra återstoden uppslammades i vatten, försattes med koncentrerad ammoniak och basen extraherades därur med eter. Den eterhaltiga lösningen torkades och indunstades och den fasta åter- stoden omkristalliserades ur isopropanol: lb-bas, färglösa kristaller,' smaitpunkt 1oo - 1o1°; Ep] 20 - s.a° (koncentration = 2 % 1 cH3oH).The filtrate of the salt pair precipitate containing the right-turning diastereomeric salt pair was evaporated on a rotary evaporator, the viscous residue was slurried in water, added with concentrated ammonia and the base extracted therefrom with ether. The ethereal solution was dried and evaporated and the solid residue was recrystallized from isopropanol: 1b base, colorless crystals, m.p. 100-110 °; Ep] 20 - s.a ° (concentration = 2% 1 cH 3 OH).

D , öenom att upplösa basen i metanol och behandla blandningen med isopropanolhaltig saltsyra och eter erhöll man dihvdrokloriden av föreningen lb i form av färglösa kristaller, smältpunkt 182 - 1a7°; EC] :° + 11,o° (koooontration = 2 % 1 çH3oH).D, by dissolving the base in methanol and treating the mixture with isopropanol-containing hydrochloric acid and ether, the dihydrochloride of compound 1b was obtained in the form of colorless crystals, m.p. 182-178 °; EC]: ° + 11, o ° (koooontration = 2% 1 çH3oH).

Exemgel gl (f)-1-[3-(3,4,5 -trimetoxi-fenoxi%2~hydroxi-propyl]-4-(2-acetoxi- fenyl)-piperazin CH3O f--\ cH3o o - cnz- CH(0H) - CH2 - N . N 3 cH3o f OCO - C53 0,03 mol l-(2-acetoxi-fenyl)-piperazin (råprodukt) och 7,2 g (0,03 mol) 3,4,5-trimetoxi-fenoxi-glycidyleter upphettades i 150 ml isopropanol så länge under återflöde att reaktionen är fullständig enligt tunnskiktskromatografikontroll. Efter avdestille- ring av lösningsmedlet erhölls genom behandling med isopropanolhal- tig saltsyra hydrokloriden och renades genom omkristallisation ur isopropanol. Smältpunkt 189 - l9l°. Utbyte 18 %. 7aøsv42-1 13 Den som utgångsämne använda 1-[2-acetyloxi-fenyl]-piperazinen erhölls på följande sätt: 192,8 g (l-mol) 2-metoxifenylpiperazin, 130 ml (1,1 mol) ben- sylklorid och 150 g (l,l0 mol) kaliumkarbonat upphettades i '300 ml xylen under återflöde tills omsättningen är fullständig enligt tunnskiktskromatografikontroll. Produkten filtrerades, lösningsmedlet avlägsnades i vakuum och produkten överfördes i hydrokloriden på sedvanligt sätt med isopropanolhahfig saltsyra (utbyte: 70 %). 60 g (0,2 mol) av den så erhållna hydrokloriden upphettades i 800 ml 63 procentig vattenhaltig bromvätesyra under återflöde, tills eterspjälkningen var fullständig (tunnskiktskromatografi- kontroll). Därefter avlägsnades lösningsmedlet i vakuum och den erhållna kristallina återstoden tvättades med eter (utbyte: 70 %). Ur dihydrobromiden frigjordes den fria basen med ut- spädd vattenhaltig ammoniak på sedvanligt sätt. lO g (0,029 mol) av den så erhållna fria basen och 15 ml tri- etylamin avkyldes i 50 ml dioxan till 50 och försattes dropp- vis med 0,032.mol acetylklorid vid en temperatur av högst 10°.Example gel gl (f) -1- [3- (3,4,5-trimethoxy-phenoxy% 2-hydroxy-propyl] -4- (2-acetoxy-phenyl) -piperazine CH3O f - \ cH3o o - cnz- CH (OH) - CH 2 - N. N 3 cH 30 f OCO - C53 0.03 mol 1- (2-acetoxy-phenyl) -piperazine (crude product) and 7.2 g (0.03 mol) 3,4,5 -trimethoxy-phenoxy-glycidyl ether was heated in 150 ml of isopropanol until refluxing was complete by thin layer chromatography control.After distilling off the solvent, the hydrochloride was obtained by treatment with isopropanol-containing hydrochloric acid and purified by recrystallization from isopropanol. Yield 18% 7a-os42 42-1 The starting 1- [2-acetyloxy-phenyl] -piperazine was obtained as follows: 192.8 g (1-mol) of 2-methoxyphenylpiperazine, 130 ml (1.1 mol) of bone syl chloride and 150 g (1.0 mol) of potassium carbonate were heated in 300 ml of xylene under reflux until the reaction is complete by thin layer chromatography control, the product is filtered, the solvent is removed in vacuo and the product is transferred was dissolved in the hydrochloride in the usual manner with isopropanol-containing hydrochloric acid (yield: 70%). 60 g (0.2 mol) of the hydrochloride thus obtained were heated in 800 ml of 63% aqueous hydrobromic acid under reflux until the ether cleavage was complete (thin layer chromatography control). Then the solvent was removed in vacuo and the resulting crystalline residue was washed with ether (yield: 70%). From the dihydrobromide, the free base with dilute aqueous ammonia was liberated in the usual manner. 10 g (0.029 mol) of the free base thus obtained and 15 ml of triethylamine were cooled in 50 ml of dioxane to 50 and added dropwise with 0.032 mol of acetyl chloride at a temperature of not more than 10 °.

Efter en timmes omrörning vid 100 avsögs den utfallande tri- etylaminhydrökloriden och lösningsmedlet avdestillerades i vakuum. I den erhållna oljiga fria basen avhydrerades utan ytterligare rening bensylgruppen på följande sätt: 0,04 mol av den fria basen löstes i 150 ml metanol och hydrerades i när- varo av 2 g 10 procentigt palladium på kol vid 500 och 5 bar.After stirring for one hour at 100 DEG C., the precipitated triethylamine hydrochloride was filtered off with suction and the solvent was distilled off in vacuo. In the resulting oily free base, the benzyl group was dehydrated without further purification as follows: 0.04 mol of the free base was dissolved in 150 ml of methanol and hydrogenated in the presence of 2 g of 10% palladium on carbon at 500 and 5 bar.

Efter avslutad väteupptagning avfiltrerades katalysatorn och lösningsmedlet avlägsnades i vakuum. Den så erhållna l-(2-ace- toxi-fenyl)-piperazinen kan omsättas direkt utan ytterligare rening.After complete hydrogen uptake, the catalyst was filtered off and the solvent was removed in vacuo. The 1- (2-acetoxy-phenyl) -piperazine thus obtained can be reacted directly without further purification.

På analogt sätt som ovannämnda exempel erhölls av vardera 0,03 mol 3,4,5-trimetoxifenoxiglycidyleter och 0,03 mol av motsvaran- de piperazinförening de i tabell 2 angivna föreningarna. Ut- gångspiperazinen erhölls vid varje tillfälle på analogt sätt med utgångsföreningen i föregående exempel, varvid i acylerings- 1203142-1 14 steget istället för acetylklorid motsvarande andra syraklorider (bensoylklorid, cyklohexankarbonsyraklorid) användes.In an analogous manner to the above examples, 0.03 mol of 3,4,5-trimethoxyphenoxy glycidyl ether and 0.03 mol of the corresponding piperazine compound each obtained the compounds listed in Table 2. The starting piperazine was obtained on each occasion in an analogous manner to the starting compound in the previous example, using in the acylation step instead of acetyl chloride corresponding to other acid chlorides (benzoyl chloride, cyclohexanecarboxylic acid chloride).

TABELL 2 Piperazinut- Rzi formel I ofimältpunkt Utbyte i % Exempel gångsförening Rl = H (hydroklorid) av det teo- nr " retiska l-(2-bensoyl- 2-bensoyloxi- 194--,l96°C 31 % 28 oxifenyl)-pi- fenyl perazin 1-(2-eyk1°- 2-cyk1onexy1- 151 - 152°c 22 z 29 hexylkarbo- karbonyloxi- nyloxifenyl)- fenyl piperazin Ekemgel 30 (3)-l-[3-(3,4,5-trimetoxi-fiæmxi)-2-acetoxi-propyl]-4-(2-metoxi- fenyl)-piperazin io g (o,o23 mel) (i)-1-[3-(3,4,s-trimetøxi-fenøxi)-2-nyaroxi- propyl]-4-(2-metoxi-fenyl)-piperazin suspenderades i 100 ml lxylen. Till produkten sattes 10 ml trietylamin och därefter tilldroppades långsamt vid rumstemperatur 9 ml acetylklorid.TABLE 2 Piperazine-Rzi formula I o Melting point Yield in% Example starting compound R1 = H (hydrochloride) of the theoretical "1- (2-benzoyl-2-benzoyloxy-194-, 196 ° C 31% 28 oxyphenyl) - piphenyl perazine 1- (2-eyk1 ° - 2-cycloonexy1-151 - 152 ° c 22 z 29 hexylcarbocarbonyloxyinyloxyphenyl) - phenyl piperazine Ekemgel 30 (3) -1- [3- (3,4,5 -trimethoxy-fi-emxy) -2-acetoxy-propyl] -4- (2-methoxy-phenyl) -piperazine io g (0.23 ml) (i) -1- [3- (3,4, s-trimethoxy- phenoxy) -2-nyaroxypropyl] -4- (2-methoxy-phenyl) -piperazine was suspended in 100 ml of xylene, 10 ml of triethylamine was added to the product and then 9 ml of acetyl chloride were slowly added dropwise at room temperature.

Lösningen lämnades 2 timmar vid rumstemperatur. Därefter av- filtrerades trietylammoniumhydrokloridem och lösningsmedlet avdestillerades i vakuum. Den erhållna råprodukten renades ge- nom torrskiktskolonnkromatografi på kiselgel (elueringsmedel kloroform/metanol 98 : 2). Hydrokloriden erhölls på sedvanligt sätt genom behandling med isopropanolhaltig saltsyra och om- kristalliserades ur isopropanol. Smältpunkt för hydrokloriden 178 - 179°c; utbyte: eo %.The solution was left for 2 hours at room temperature. Then the triethylammonium hydrochloride was filtered off and the solvent was distilled off in vacuo. The obtained crude product was purified by dry layer column chromatography on silica gel (eluent chloroform / methanol 98: 2). The hydrochloride was obtained in the usual manner by treatment with isopropanol-containing hydrochloric acid and recrystallized from isopropanol. Melting point of the hydrochloride 178 - 179 ° C; yield: eo%.

Exemgel 3l och 32 - (j)-l-[3-(3,4,5-trimetoxi-fenoxi)-2-(tienyl-(2)-karbonyloxi) propyl]-4-(2-metoxi-fenyl)-piperazin 7863742-1 15 l _cn3o °°3a; CH O O - CH - CH - CH - 0 - CO -Jís > 15 g (0,03l9 mol) (1)-l-[3-(3,4,5-trimetoxifenoxi)-2-hydroxi- propyl]-4-(2-metoxifenyl)-piperazin-dihydroklorid och 3,3 g trietylamin suspenderades i 100 ml xylen. Under omrörning för- satte man blandningen droppvis med 4,7 g (0,03l9 mol) tiofen- 2-karbonsyraklorid vid rumstemperatur. Man omrörde ytterligare en timme vid rumstemperatur. Därefter avfiltrerades den ut- fallande trietylammoniumhydrokloriden och lösningen indun- stades under förminskat tryck. Återstoden upptogs 1 eter och försattes med isopropanolhaltig HCl. Den erhållna dihydroklo- riden omkristalliserades ur isopropanol.Example gel 31 and 32 - (j) -1- [3- (3,4,5-trimethoxy-phenoxy) -2- (thienyl- (2) -carbonyloxy) propyl] -4- (2-methoxy-phenyl) - piperazine 7863742-1 15 l _cn3o °° 3a; CH 0 O - CH - CH - CH - O - CO - Jis> 15 g (0.0319 mol) (1) -1- [3- (3,4,5-trimethoxyphenoxy) -2-hydroxypropyl] -4 - (2-Methoxyphenyl) -piperazine dihydrochloride and 3.3 g of triethylamine were suspended in 100 ml of xylene. With stirring, the mixture was added dropwise with 4.7 g (0.03 l9 mol) of thiophene-2-carboxylic acid chloride at room temperature. Stir for another hour at room temperature. The precipitated triethylammonium hydrochloride was then filtered off and the solution was evaporated under reduced pressure. The residue was taken up in ether and added with isopropanol-containing HCl. The resulting dihydrochloride was recrystallized from isopropanol.

Smältpunkt för dihydrokloriden 198 - l99° (substansen innehöll 1 mol isopropanol som kristallsolvens). Utbyte: 42 % Motsvarande tienyl-(3)-förening skedde på analogt sätt.Melting point of the dihydrochloride 198-199 ° (the substance contained 1 mole of isopropanol as crystal solvent). Yield: 42% The corresponding thienyl (3) compound took place in an analogous manner.

Smältpunkt för dihydrokloriden 193 - 1940. Utbyte: 48 % Exemgel 33 (i)-l-[3-(3,4,5-trimetoxi-fenoxi)-2-(tienyl-(2)-karbonyloxi)- propyl]-4-[2-(tienyl-(2)-karbonyloxi)-fenyl]~piperazin I I oco-lís/Ü H-co oc s 9 / \ I c N N _ -C _ __* flsco __ cH2 H H2 Hjco Man suspenderade 7 g (0,0l67 mol) (1)-l-[3-(3,4,5-trimetoxi- fenoxi)-2-hydroxi-propyl]~4-(2-hydroxi-fenyl)-piperazin i 100 ml dioxan och 4 ml trietylamin. Man tillsatte portionsvis under omrörning vid rumstemperatur 5 g (0,034 mol) tiofen-2- karbonsyraklorid. Efter avslutad tillsats omrörde man ytter- 78637 42-1 16 ligare 6 timmar och lät blandningen därefter stå vid rumstempe- ratur. Den bildade trietylammoniumhydrokloriden avfiltrerades och lösningsmedlet avdestillerades i vakuum. Den kvarblivande oljiga produkten upptogs i 100 ml eter, försattes med isopro- panolhaltig saltsyra till sur reaktion och den utfallande hy- drokloriden avsögs. För rening omkristalliserades blandningen ur isopropanol. Utbyte: 61 %. Smältpunkt för hydrokloriden 221 - 222°.Melting point of the dihydrochloride 193 - 1940. Yield: 48% Example gel 33 (i) -1- [3- (3,4,5-trimethoxy-phenoxy) -2- (thienyl- (2) -carbonyloxy) -propyl] -4 - [2- (thienyl- (2) -carbonyloxy) -phenyl] ~ piperazine II oco-lys / Ü H-co oc s 9 / \ I c NN _ -C _ __ * fl sco __ cH2 H H2 Hjco Man suspended 7 g (0.0l67 mol) (1) -1- [3- (3,4,5-trimethoxyphenoxy) -2-hydroxy-propyl] -4- (2-hydroxy-phenyl) -piperazine in 100 ml of dioxane and 4 ml of triethylamine. 5 g (0.034 mol) of thiophene-2-carboxylic acid chloride were added portionwise with stirring at room temperature. After the addition was complete, the mixture was stirred for a further 6 hours and then allowed to stand at room temperature. The triethylammonium hydrochloride formed was filtered off and the solvent was distilled off in vacuo. The residual oily product was taken up in 100 ml of ether, added with isopropanol-containing hydrochloric acid to an acid reaction and the precipitated hydrochloride was filtered off with suction. For purification, the mixture was recrystallized from isopropanol. Yield: 61%. Melting point of the hydrochloride 221 - 222 °.

Claims (3)

'? 7eaz742-1 PATENTKRAV Förfarande för framställning av föreningar med den allmänna formeln' CH'? 7eaz742-1 CLAIM Process for the preparation of compounds of the general formula 'CH 1. 3 . cnao o-cnz-gn-cna-N n-nz I I cnao OR, \--/ vari Rl betecknar väte, alkanoyl med1. 3. cnao o-cnz-gn-cna-N n-nz I I cnao OR, \ - / wherein R 1 represents hydrogen, alkanoyl with 2. - 6 kolatomer, alkenoyl med2. - 6 carbon atoms, alkenoyl med 3. - 6 kolatomer, bensoyl, alkoxibensoyl med 1 - 4 kolatomer, nikoti- noyl eller tienylkarbonyl och R2 betecknar en eventuellt med grupperna R3 och R4 substituerad fenyl-, naftyl- eller pyridylgrupp, vari R3 och R4 är lika eller olika och betecknar väte, hydroxyl, fluor, klor, brom, nitro, trifluormetyl, alkyl med 1 - 6 kolatomer, alkoxi med l - 6 kolatomer, alkyltio med l - 6 kolatomer, alkanoyl med 2 - 6 kol- atomer, amino, acylamino eller acyloxi, varvid i de båda sistnämnda grupperna acyl kan vara en för Rl angiven acylgrupp, och deras salter, k ä n n e t e c k n a t därav, att man omsätter en förening med formeln cußc ~ . _ j 01130 / \ or II _ cußo '__ med en förening med formeln ' / I 2 z-N NR ' ^ III \__/ . vari Y och Z alltid är olika och antingen betecknar väte eller gruppen -CH2-CH(ORl)-CH2-V, vari V betecknar klor, brom eller jod eller kan, om Rl betecknar väte, tillsammans med hydroxigruppen även -_.........._.. 7.--...........- _ 1aas742-1 f* - _ . ' I s nu nu - »».- -. bilda en etylenoxidring, och eventuellt reducerar en eller två nitrogrupper till aminogrupper och/eller acylerar de erhållna före- ningarna med en syra resp. ett syraderivat motsvarande gruppen Rl, och att man eventuellt överför de erhållna föreningarna i sina syraadditionssalter.3 to 6 carbon atoms, benzoyl, alkoxybenzoyl having 1 to 4 carbon atoms, nicotinoyl or thienylcarbonyl and R 2 represents a phenyl, naphthyl or pyridyl group optionally substituted by the groups R 3 and R 4, wherein R 3 and R 4 are the same or different and represent hydrogen , hydroxyl, fluorine, chlorine, bromine, nitro, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkylthio of 1 to 6 carbon atoms, alkanoyl of 2 to 6 carbon atoms, amino, acylamino or acyloxy, wherein in the latter two groups acyl may be an acyl group indicated for R1, and their salts, characterized in that a compound of the formula cußc ~ is reacted. _ j 01130 / \ or II _ cußo '__ with a compound of the formula' / I 2 z-N NR '^ III \ __ /. wherein Y and Z are always different and either represent hydrogen or the group -CH 2 -CH (OR 1) -CH 2 -V, wherein V represents chlorine, bromine or iodine or, if R 1 represents hydrogen, together with the hydroxy group also -_... ......._ .. 7. - ...........- _ 1aas742-1 f * - _. 'I s nu nu - »» .- -. form an ethylene oxide ring, and optionally reduce one or two nitro groups to amino groups and / or acylate the obtained compounds with an acid resp. an acid derivative corresponding to the group R1, and that the compounds obtained are optionally transferred to their acid addition salts.
SE7803742A 1977-04-04 1978-04-03 PROCEDURE FOR THE PREPARATION OF TRIMETOXIFENOXY-PROPYL-PIPEREZINE DERIVATIVES SE435507B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB14100/77A GB1583372A (en) 1977-04-04 1977-04-04 1-(3-(3,4,5-trimethoxyphenoxy)-2-hydroxypropyl)-4-aryl piperazine derivatives

Publications (2)

Publication Number Publication Date
SE7803742L SE7803742L (en) 1978-10-05
SE435507B true SE435507B (en) 1984-10-01

Family

ID=10034980

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7803742A SE435507B (en) 1977-04-04 1978-04-03 PROCEDURE FOR THE PREPARATION OF TRIMETOXIFENOXY-PROPYL-PIPEREZINE DERIVATIVES

Country Status (23)

Country Link
JP (1) JPS6038383B2 (en)
AR (1) AR222149A1 (en)
AT (1) AT360997B (en)
AU (1) AU516315B2 (en)
BE (1) BE865642A (en)
CA (1) CA1124718A (en)
CH (1) CH638795A5 (en)
CS (1) CS249503B2 (en)
DE (1) DE2814168A1 (en)
DK (1) DK145225C (en)
ES (1) ES468486A1 (en)
FI (1) FI69627C (en)
FR (1) FR2395264A1 (en)
GB (1) GB1583372A (en)
HU (1) HU179952B (en)
MX (1) MX6120E (en)
NL (1) NL7803540A (en)
NO (1) NO149209C (en)
PL (1) PL112249B1 (en)
SE (1) SE435507B (en)
SU (1) SU893133A3 (en)
YU (1) YU40513B (en)
ZA (1) ZA781889B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335126A (en) * 1977-03-10 1982-06-15 Degussa Aktiengesellschaft 1-[3-(3,4,5-Trimethoxyphenoxy)-2-hydroxy-propyl]-4-aryl-piperazine-derivatives having pharmaceutical activity
FR2488892A2 (en) * 1977-04-04 1982-02-26 Degussa NOVEL 1- (3- (3,4,5-TRIMETHOXYPHENOXY) -2-HYDROXYPROPYL) -4-ARYL-PIPERAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS A MEDICINAL PRODUCT
DE2824764A1 (en) * 1978-06-06 1979-12-20 Hoechst Ag NEW PYRIDYL PIPERAZINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION
DE3023369A1 (en) * 1980-06-23 1982-01-14 Boehringer Mannheim Gmbh, 6800 Mannheim ARYLOXYPROPANOLAMINE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
FR2568878B1 (en) * 1984-08-07 1986-11-21 Cortial NOVEL (PHENYLPIPERAZINYLETHYLAMINE ETHOXY) -4 PHENOL DERIVATIVES, THEIR PREPARATION METHOD AND THEIR THERAPEUTIC APPLICATION

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA967965A (en) * 1968-12-24 1975-05-20 Hoffmann-La Roche Limited Aromatic ethers and process for the manufacture thereof
FR2068051A5 (en) * 1969-11-26 1971-08-20 Robert Jean
SE397088B (en) * 1972-06-17 1977-10-17 Sumitomo Chemical Co PROCEDURE FOR PREPARING NEW 2-PROPANEL DERIVATIVES
DE2235597A1 (en) * 1972-07-20 1974-01-31 Boehringer Mannheim Gmbh SINGLE SQUARE CLIP ON 3- (5,6,7,8TETRAHYDRONAPHTH-1-YL-OXY) -PROPYL SQUARE CLIP FOR -PIPERAZINE DERIVATIVES AND METHOD FOR THEIR PRODUCTION

Also Published As

Publication number Publication date
JPS53130682A (en) 1978-11-14
PL112249B1 (en) 1980-10-31
FI781009A (en) 1978-10-05
NL7803540A (en) 1978-10-06
DK146678A (en) 1978-10-05
FR2395264A1 (en) 1979-01-19
GB1583372A (en) 1981-01-28
CS249503B2 (en) 1987-03-12
DE2814168A1 (en) 1978-10-05
AT360997B (en) 1981-02-10
ES468486A1 (en) 1979-01-16
DE2814168C2 (en) 1989-02-16
JPS6038383B2 (en) 1985-08-31
FI69627C (en) 1986-03-10
DK145225B (en) 1982-10-11
BE865642A (en) 1978-10-03
MX6120E (en) 1984-11-19
NO149209B (en) 1983-11-28
AU516315B2 (en) 1981-05-28
ZA781889B (en) 1979-03-28
HU179952B (en) 1983-01-28
SU893133A3 (en) 1981-12-23
YU76778A (en) 1982-10-31
CH638795A5 (en) 1983-10-14
FR2395264B1 (en) 1980-03-07
ATA233078A (en) 1980-07-15
CA1124718A (en) 1982-06-01
AR222149A1 (en) 1981-04-30
YU40513B (en) 1986-02-28
AU3470378A (en) 1979-10-11
SE7803742L (en) 1978-10-05
FI69627B (en) 1985-11-29
NO781159L (en) 1978-10-05
DK145225C (en) 1983-04-11
NO149209C (en) 1984-03-07
PL205745A1 (en) 1979-05-07

Similar Documents

Publication Publication Date Title
KR920005113B1 (en) Process for the preparation of antipsychotic 1-fluoro phenyl butyl-4-(2-pyrimidinyl)piperazinyl derivatives
CA2247772A1 (en) .alpha.-substituted phenylpropionic acid derivative and medicine containing the same
US3766180A (en) 3-heterocyclicamino-4-chloro-1,2,5-thiadiazoles
NO155805B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVITY 2- (4- (DIPHENYLMETHYL) -1-PIPERAZINYL) -ACDIC ACIDS AND THEIR AMIDS AND NON-TOXIC SALTS.
EP0190015B1 (en) Novel 4h-1-benzopyran-4-ones and their sulphur containing analogs
US3974158A (en) 2-(Substituted anilino)methylmorpholines
HU190827B (en) Process for preparing 2-/4/-/4,4-dialkyl-1,2,6-piperidindion-1-yl/-butyl/-1-piperazinyl/-pyridines
US4404384A (en) O-[3-(4-Substituted-piperazin-1-yl)-2-hydroxypropyl]-hydroxylamines
HUT73526A (en) Benzazepine derivative, pharmaceutical composition containing the same, and intermediate for the same
EP0549796A1 (en) Diphenylpiperazine derivative and drug for circulatory organ containing the same
CZ418597A3 (en) 1,6-disubstituted isochromans for treating headache during migraine
SE435507B (en) PROCEDURE FOR THE PREPARATION OF TRIMETOXIFENOXY-PROPYL-PIPEREZINE DERIVATIVES
JPS5949225B2 (en) Method for producing compounds
HU182290B (en) Process for producing phenyl-piperazine derivatives of 1,3,4-oxadiazolyl-phenols
HU220971B1 (en) Process for producing 0-(3-amino-2-hidroxy-propyl)-hidroxim acid halogenids
Chapman et al. Synthesis of diastereomeric ketoconazole analogs
US3040031A (en) N-heterocyclic compounds
US5536836A (en) Process for the preparation of 2-(4-[4-(4-chloro-1-pyrazolyl)butyl]-1-piperazinyl)pyrimidine (Lesopitron)
US3929902A (en) 1-Phenyl-2, 3-butadien-1-ols
CA1110642A (en) Process for the preparation of o-alkylated hydroxylamines
HU189226B (en) Process for producing basic oxime-ethers
JPS6175A (en) Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl) piperazine derivative
EP0084292B1 (en) N,n-disubstituted alkenamides and phenylalkenamides, processes for their production and their use as pharmaceuticals
EP0574271A2 (en) Novel benzyl and benzhydryl alcohols
US3268533A (en) 4-aminophenylcyclopropyl ketones

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 7803742-1

Effective date: 19911108

Format of ref document f/p: F